At this stage, the p1a/b will only be investigating CPACS in Anthracyclines (3/18 drugs in the earlier table).
@Brucekoala They can't talk about it because it's an extension of the collaboration work on Zan that has not yet been published. The significance of this paper will only be truly understood in hindsight IMO.
Watch for the ICO Society conference where Dent advises clinicians (globally) that almost half of all chemotherapeutics significantly reduce HCM viability - and they've found a drug that might mitigate this...
Cardioprotection thread, page-237
-
- There are more pages in this discussion • 368 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |